Adtalem Global Education upgraded to Outperform from Neutral at Baird

Baird analyst Jeffrey Meuler upgraded Adtalem Global Education to Outperform from Neutral with a price target of $55, up from $47. Healthcare education was highly disrupted during COVID, which is increasingly normalizing, and there may be counter-cyclical demand drivers with some signs of a weakening consumer, the analyst tells investors in a research note. The firm says a better integrated portfolio, new management, and various in-flight initiatives “add self-help factors” for Adtalem. It believes the company’s operating metrics are improving and that Adtalem’s faster growth should be sustainable.